Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines - PubMed (original) (raw)

Review

Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines

J Dutcher et al. Med Oncol. 2001.

Abstract

The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regarding the efficacy of the high-dose interleukin-2 (IL2)/lymphokine-activated killer cell (LAK cell) regimen piloted at the NCI in the treatment of renal cell cancer. Since those initial studies, the CWG has conducted a series of clinical trials, often with correlative immunologic investigations, to evaluate combination immunotherapy in attempts to enhance the efficacy of IL-2 or to reduce toxicity. Subsequently, the CWG conducted trials to demonstrate the activity of lower-dose outpatient combination cytokine regimens to help determine their role in the armamentarium of treatment for metastatic renal cell cancer. This has culminated in a phase III randomized trial comparing the activity of high-dose IL-2 with the activity of outpatient IL-2 plus interferon-alpha. The CWG also has honed the management of both high-dose IL-2 and outpatient IL-2 regimens to make these safer in the hands of experienced clinicians. In addition, the CWG has produced a series of carefully conducted clinical trials of new cytokines, again attempting to define their clinical efficacy as anticancer agents. These include studies of IL-4, IL-6, and IL-12. Currently, the CWG is conducting studies with new approaches to IL-2 therapy, as well as planning trials with new agents for treatment of renal cell cancer. This review describes these efforts conducted over the past 15 yr.

PubMed Disclaimer

Cited by

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014.
Dutcher JP, Schwartzentruber DJ, Kaufman HL, Agarwala SS, Tarhini AA, Lowder JN, Atkins MB. Dutcher JP, et al. J Immunother Cancer. 2014 Sep 16;2(1):26. doi: 10.1186/s40425-014-0026-0. J Immunother Cancer. 2014. PMID: 31546315 Free PMC article. Review.
Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2.
Khong B, Lawson BO, Ma J, McGovern C, Van Atta JK, Ray A, Khong HT. Khong B, et al. BMC Cancer. 2018 Oct 20;18(1):1007. doi: 10.1186/s12885-018-4810-y. BMC Cancer. 2018. PMID: 30342473 Free PMC article.
IL-2 and Beyond in Cancer Immunotherapy.
Wrangle JM, Patterson A, Johnson CB, Neitzke DJ, Mehrotra S, Denlinger CE, Paulos CM, Li Z, Cole DJ, Rubinstein MP. Wrangle JM, et al. J Interferon Cytokine Res. 2018 Feb;38(2):45-68. doi: 10.1089/jir.2017.0101. J Interferon Cytokine Res. 2018. PMID: 29443657 Free PMC article. Review.
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.
Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N, Morse MA, Wong MKK, Dutcher JP. Curti B, et al. J Immunother Cancer. 2017 Dec 19;5(1):102. doi: 10.1186/s40425-017-0307-5. J Immunother Cancer. 2017. PMID: 29254506 Free PMC article. Clinical Trial.
Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment.
Jain D, Ahmad T, Cairo M, Aronow W. Jain D, et al. Ann Transl Med. 2017 Sep;5(17):348. doi: 10.21037/atm.2017.06.35. Ann Transl Med. 2017. PMID: 28936442 Free PMC article. Retracted. Review.

References

1. Dermatol Clin. 2000 Jan;18(1):169-75, x - PubMed
1. Cancer Res. 1991 Oct 15;51(20):5687-93 - PubMed
1. J Exp Med. 1990 Mar 1;171(3):629-36 - PubMed
1. Blood. 1997 Oct 1;90(7):2541-8 - PubMed
1. J Clin Oncol. 1992 Nov;10(11):1802-9 - PubMed

Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines - PubMed (original) (raw)